Observational study reveals interleukin variations in inattentive ADHD correlate with conduct disorder, suggesting these immune shifts reflect comorbidities rather than medication response.
Abstract Background. Inflammatory cytokines are involved in attention deficit/hyperactivity disorder (ADHD), a highly prevalent neurodevelopmental disorder. Objetive. To quantify baseline levels of pro- and anti-inflammatory cytokines and their changes after treatment with methylphenidate (MPH) in prepubertal children with ADHD. Methods. A total of 31 prepubertal children with ADHD were recruited. Based on the scores of the NICHQ Vanderbilt scales, the children were subclassified in only two ADHD presentations: ADHD-Attention Deficit (n= 13) or ADHD-Combined (n= 18). The children were also screened for Oppositional Desafiant Conduct Disorder (ODCD) and Anxiety Disorder. Blood samples were drawn at 09:00 h and after 4,63 ± 1,87 months of treatment. Four proinflammatory cytokines [interleukin-1 beta (IL-1β), IL-5, IL-6, and tumour necrosis factor alpha (TNFα)] and three anti-inflammatory cytokines (IL-4, IL-10, IL-13) were measured using a Luminex® assay. Statistic: Factorial analysis (Stata 15.1) was performed using instants (baseline – post-treatment), presentations, and ODCD as factors. Results. Overall, there were no differences induced by treatment in the concentrations of interleukins (ILs) analysed in our group of pre-pubertal children with ADHD. Grouped by Presentations, the differences detected are present almost exclusively in ADHD-AD Presentation, usually with a concentration profile opposite to that observed in ADHD-C, and with interactions between comorbid Factors, with the ILs that reach the greatest statistical significance being IL-1β (p = 0.01) and IL-13 (p = 0.006). These differences are probably related to the ODCD factor, and these differences disappear after treatment. Conclusion. The changes that we described in inflammatory cytokines in prepubertal children only in ADHD-AD presentation are probably related to comorbidities (specifically ODCD) and disappear after treatment, but do not be involved in the highly clinically favourable response to MPH in prepubertal children.
No takes yet. Share an insight, caveat, or question.
Villén et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: